Media stories about Edap Tms (NASDAQ:EDAP) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Edap Tms earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 47.7016758742248 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the headlines that may have impacted Accern’s scoring:
- High Intensity Focused Ultrasound System Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast by … (newspharmaceuticals.com)
- Analysts Call Attention: EDAP TMS SA (EDAP) (mostvolatilestocks.com)
- Extracorporeal Shock Wave Lithotripsy Machine Market Development by 2023: EDAP TMS, Siemens, MTS and … (truthtoday24.com)
- High-intensity Focused Ultrasound System Market Development by 2023: EDAP TMS, Philips Healthcare … (newspharmaceuticals.com)
- High Intensity Focused Ultrasound System Market Analysis, Share, Opportunities, and Region Forecast 2018 to 2025 (digitaljournal.com)
Several brokerages have recently commented on EDAP. Zacks Investment Research upgraded Edap Tms from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Wednesday, January 10th. HC Wainwright set a $7.00 target price on Edap Tms and gave the stock a “buy” rating in a research note on Thursday, March 29th. Finally, ValuEngine downgraded Edap Tms from a “hold” rating to a “sell” rating in a research note on Sunday, December 31st.
Edap Tms (NASDAQ:EDAP) last issued its earnings results on Tuesday, March 27th. The medical equipment provider reported $0.01 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.01. Edap Tms had a positive return on equity of 23.25% and a negative net margin of 2.12%. The company had revenue of $12.60 million during the quarter, compared to the consensus estimate of $12.87 million.
WARNING: “Edap Tms (EDAP) Earning Somewhat Favorable Press Coverage, Analysis Shows” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://stocknewstimes.com/2018/04/19/edap-tms-edap-earning-somewhat-favorable-press-coverage-analysis-shows.html.
Edap Tms Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.